Stock Scorecard
Stock Summary for Rhythm Pharmaceuticals Inc (RYTM) - $65.77 as of 7/4/2025 2:06:02 AM EST
Total Score
9 out of 30
Safety Score
39 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for RYTM
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for RYTM
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for RYTM
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for RYTM
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for RYTM (39 out of 100)
| Stock Price Rating (Max of 10) | 9 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for RYTM
Financial Details for RYTM
Company Overview |
|
|---|---|
| Ticker | RYTM |
| Company Name | Rhythm Pharmaceuticals Inc |
| Country | USA |
| Description | Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 65.77 |
| Price 4 Years Ago | 9.98 |
| Last Day Price Updated | 7/4/2025 2:06:02 AM EST |
| Last Day Volume | 628,374 |
| Average Daily Volume | 584,844 |
| 52-Week High | 69.89 |
| 52-Week Low | 40.46 |
| Last Price to 52 Week Low | 62.56% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 21.93 |
| Sector PE | 40.90 |
| 5-Year Average PE | -23.23 |
| Free Cash Flow Ratio | 39.38 |
| Industry Free Cash Flow Ratio | 17.71 |
| Sector Free Cash Flow Ratio | 32.91 |
| Current Ratio Most Recent Quarter | 3.30 |
| Total Cash Per Share | 1.67 |
| Book Value Per Share Most Recent Quarter | 0.30 |
| Price to Book Ratio | 219.74 |
| Industry Price to Book Ratio | 34.53 |
| Sector Price to Book Ratio | 30.76 |
| Price to Sales Ratio Twelve Trailing Months | 31.11 |
| Industry Price to Sales Ratio Twelve Trailing Months | 121.97 |
| Sector Price to Sales Ratio Twelve Trailing Months | 35.60 |
| Analyst Buy Ratings | 8 |
| Analyst Strong Buy Ratings | 4 |
Share Statistics |
|
| Total Shares Outstanding | 63,622,000 |
| Market Capitalization | 4,184,418,940 |
| Institutional Ownership | 107.02% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -41.11% |
| Reported EPS 12 Trailing Months | -2.80 |
| Reported EPS Past Year | -0.81 |
| Reported EPS Prior Year | -4.49 |
| Net Income Twelve Trailing Months | -170,021,000 |
| Net Income Past Year | -260,602,000 |
| Net Income Prior Year | -184,678,000 |
| Quarterly Revenue Growth YOY | 25.90% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | -143.70% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 106,095,000 |
| Total Cash Past Year | 89,137,000 |
| Total Cash Prior Year | 60,081,000 |
| Net Cash Position Most Recent Quarter | 106,095,000 |
| Net Cash Position Past Year | 87,797,000 |
| Long Term Debt Past Year | 1,340,000 |
| Long Term Debt Prior Year | 1,340,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 0.94 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 21,729,000 |
| Total Stockholder Equity Prior Year | 169,759,000 |
| Total Stockholder Equity Most Recent Quarter | 163,089,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -153,487,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.41 |
| Free Cash Flow Past Year | -113,879,000 |
| Free Cash Flow Prior Year | -136,204,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.18 |
| MACD Signal | 0.54 |
| 20-Day Bollinger Lower Band | 47.85 |
| 20-Day Bollinger Middle Band | 58.39 |
| 20-Day Bollinger Upper Band | 68.92 |
| Beta | 2.30 |
| RSI | 48.64 |
| 50-Day SMA | 55.15 |
| 150-Day SMA | 37.86 |
| 200-Day SMA | 30.72 |
System |
|
| Modified | 7/3/2025 9:47:24 AM EST |